reference/24899055

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/24899055

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, N.I.H., Extramural
endingPage	1498
issn	0344-5704 1432-0843
issueIdentifier	6
pageRange	1487-1498
publicationName	Cancer Chemotherapy and Pharmacology
startingPage	1487
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_9f7a15b500dda83a0e0be55a44d543fb http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_563523465e5c7243516d66d0ed89f646 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_b605da4c876c47d2ad00af4ccc3d3913 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_fd2484f52358775eb44cf931772fba95 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_f420cbbd518c4fab42e88d9851c9ed9d http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_44b710a5517699e8f08f1428650576a2
bibliographicCitation	Liu Q, Sun JD, Wang J, Ahluwalia D, Baker AF, Cranmer LD, Ferraro D, Wang Y, Duan J, Ammons WS, Curd JG, Matteucci MD, Hart CP. TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. Cancer Chemotherapy and Pharmacology. 2012 Mar 02;69(6):1487–98. doi: 10.1007/s00280-012-1852-8.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8be8b725ea8fdf035c4239915eec4e53 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_421c8784656d56de4140d4918bebff0c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_225808be49346eba179487114e735ab7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e86012ae9cc5c9b6101e2c8578afb7be http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a0cf56c40a08dba3462ec74c248f2ae1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b8fed138f5d15fec7a6501c4df7b485c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c686431d45de9365291465771c0aa50f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d782a6c3106b77cc02d64dfda9ca4cf5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_55f6ca308ca766ba4e0c34f55f517671 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_014e81d18a528d867f03538e0f50332d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_735dc4e75e3ee5585877b5949a16e044 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7b206b483a3e027201ae7a04060a9fdd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6fb13e117356dd983510b4644aa4c3f9
date	2012-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1007/s00280-012-1852-8 https://pubmed.ncbi.nlm.nih.gov/PMC3985381 https://pubmed.ncbi.nlm.nih.gov/22382881
isPartOf	https://portal.issn.org/resource/ISSN/1432-0843 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/2664 https://portal.issn.org/resource/ISSN/0344-5704
language	English
source	https://www.crossref.org/ https://scigraph.springernature.com/ https://pubmed.ncbi.nlm.nih.gov/
title	TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules
discusses	http://id.nlm.nih.gov/mesh/M0147530 http://id.nlm.nih.gov/mesh/M0017642 http://id.nlm.nih.gov/mesh/M0004505 http://id.nlm.nih.gov/mesh/M0227083 http://id.nlm.nih.gov/mesh/M0014907 http://id.nlm.nih.gov/mesh/M0184558 http://id.nlm.nih.gov/mesh/M0009679 http://id.nlm.nih.gov/mesh/M0550416 http://id.nlm.nih.gov/mesh/M0009376 http://id.nlm.nih.gov/mesh/M0443608 http://id.nlm.nih.gov/mesh/M000754277 http://id.nlm.nih.gov/mesh/M0005997 http://id.nlm.nih.gov/mesh/M0016714 http://id.nlm.nih.gov/mesh/M0003242
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7738 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8766 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135410875 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148124 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6914 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8448 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60838 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11984561 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60750 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31703 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7306 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5394 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5702198 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8983

Incoming Links

Predicate

Subject

http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129221764
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129439837
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127639621
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129520161
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135945851
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129159660
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129430288

Total number of triples: 79.